Julia Stingl

Professor

RWTH Aachen

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Medical Science Medical Science professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Julia Stingl is a faculty member at RWTH Aachen in Germany. Her research focuses on pharmacogenetics, adverse drug reactions, and drug metabolism, with recent publications analyzing large-scale datasets related to cytochrome P450 enzymes and the implementation of pharmacogenetic panels to prevent adverse drug reactions. Additionally, she investigates the prevalence of treatment issues in antihypertensive drug users and the impact of inhalation therapies on emergency department visits.

Articles (18)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (10)

Barbara Schnierle

Paul-Ehrlich-Institut

GERMANY

View details

Marie-Luise Herrlein

Paul-Ehrlich-Institut

GERMANY

View details

Albrecht Eisert

Assistent Professor

University Hospital

GERMANY

View details

Jonathan Eisert

Technische Universität Darmstadt

GERMANY

View details

Roberto Viviani

University of Innsbruck

AUSTRIA

View details

Panagiotis Ferentinos

Associate Professor of Psychiatry

National and Kapodistrian University of Athens - Faculty of Medicine

GREECE

View details

Saskia Wilhelmy

University Hospital

GERMANY

View details

Corinna Ernst

University of Cologne

GERMANY

View details

Emilio Guirao-Arrabal

SPAIN

View details

Kathrin Blagec

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julia Stingl

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Prevalence and determinants of over- and undertreatment among users of antihypertensive drugs in the general population: the Rhineland Study

The gradient model of brain organization in decisions involving "empathy for pain"

Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study

Inhalation therapies in COPD - adverse drug reactions impact on emergency department presentations

Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports

Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera

Inhalation therapies in COPD - adverse drug reactions impact on emergency department presentations.

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes

Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports.

Optimal@NRW: optimized acute care of nursing home residents using an intersectoral telemedical cooperation network - study protocol for a stepped-wedge trial.

Emergency Department Visits Due to Dyspnea: Association with Inhalation Therapy in COPD and Cases with Adverse Drug Reactions.

Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective.

Molecular Genetic Screening in Patients With ACE Inhibitor/Angiotensin Receptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angioedema Genes.

Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.

Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial.

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes

Collaborators (10)

Barbara Schnierle

Marie-Luise Herrlein

Albrecht Eisert

Jonathan Eisert

Roberto Viviani

Panagiotis Ferentinos

Saskia Wilhelmy

Corinna Ernst

Emilio Guirao-Arrabal

Kathrin Blagec

Make your next move.